PR方案治疗慢性丙型肝炎患者ITPA基因rs1127354位点多态性与利巴韦林相关性溶血关系探讨*

doi:10.3969/j.issn.1672-5069.2020.04.012

摘要/Abstract

摘要： 目的探讨应用标准抗病毒(PR)方案治疗慢性丙型肝炎(CHC)患者三磷酸次黄嘌呤核苷(ITPA)基因多态性对抗病毒疗效及其对利巴韦林(RBV)相关性溶血的影响。方法 2016年3月~2018年3月我院收治的CHC患者235例,给予聚乙二醇化干扰素α-2a联合RBV治疗24～48 w。采用基因测序法检测血ITPA基因rs1127354位点多态性。结果经检测,发现ITPA基因型rs1127354位点为CC型193例和AA/AC型42例;在完成24周疗程的188例(CC型152例和AA/AC型36例)CHC患者中, AA/AC型患者快速病毒学应答和早期病毒学应答率分别为44.4%和47.2%,与CC型的42.1%和42.7%比,无显著性差异(P>0.05),而持续病毒学应答率为72.2%,显著高于CC型的53.3%(P<0.05);在治疗4周、8周、12周和24周,AA/AC型患者Hb水平分别为(138.2±14.7) g/L、(130.5±12.6) g/L、(123.7±12.5)g/L和(118.0±10.2)g/L,显著高于CC型【分别为(132.3±13.9)g/L、(113.1±10.5)g/L、(108.4±9.4)g/L和(106.7±11.3)g/L,P＜0.05】。结论在PR方案治疗的慢性丙型肝炎患者,ITPA基因(rs1127354)CC基因型较AA/AC基因型更易发生RBV 相关性溶血,而ITPA基因型与抗病毒效果密切相关,临床应加以重视和预防性处理。

关键词: 慢性丙型肝炎, 肌苷三磷酸酶基因型, 利巴韦林相关溶血, 持续病毒学应答

Abstract: Objective The aim of this study was to explore the impact of inosine triphosphatase genotype (ITPA) gene rs1127354 polymorphism on ribavirin (RBV)-related hemolysis in patients with chronic hepatitis C (CHC) receiving pegylated interferon alpha-2a and RBV (PR) therapy. Methods 235 patients with CHC were recruited in our hospital between March 2016 and March 2018, and all patients received PR therapy for 24 to 48 weeks. The blood ITPA gene locus rs1127354 were detected by gene sequencing. Results The gene sequencing showed that ITPA genotype rs1127354 locus were CC in 93 and AA/AC in 42; 188 patients with CHC (152 with CC and 36 with AA/AC) completed the 24-week antiviral regimen, and the rapid virological response (RVR) and early virological response (EVR) in patients with genotype AA/AC were 44.4% and 47.2%, not significantly different as compared to 42.1% and 42.7% in those with genotype CC(P>0.05), while the sustained virological response (SVR) was 72.2%, significantly higher than 53.3%(P<0.05) in patients with genotype CC; at the end of week 4, 8, 12 and 24, blood hemoglobin levels in patients with genotype AA/AC were (138.2±14.7) g/L, (130.5±12.6) g/L, (123.7±12.5)g/L and (118.0±10.2)g/L, significantly higher than 【(132.3±13.9)g/L, (113.1±10.5)g/L, (108.4±9.4)g/L and (106.7±11.3)g/L, respectively, P＜0.05】 in patients with genotype CC. Conclusion The CHC patients with ITPA genotype CC are more prone to RBV-related hemolysis during PR antiviral therapy, which should be taken into consideration in clinical decision-making process.

Key words: Hepatitis C, Inosine triphosphatase genotype, Ribavirin-related hemolysis, Sustained virological response

徐金凤, 安红杰, 何文艳, 艾红, 赵崇山, 赵应飞, 董波, 周丽华, 吴晶. PR方案治疗慢性丙型肝炎患者ITPA基因rs1127354位点多态性与利巴韦林相关性溶血关系探讨^*[J]. 实用肝脏病杂志, 2020, 23(4): 500-503.

Xu Jinfeng, An Hongjie, He Wenyan, et al. Impact of ITPA gene rs1127354 polymorphism on ribavirin-related hemolysis in patients with chronic hepatitis C receiving PR therapy[J]. Journal of Practical Hepatology, 2020, 23(4): 500-503.

参考文献

[1]曹风华, 经继生, 赵伟, 等. 大剂量普通α-干扰素与聚乙二醇化α-干扰素联合利巴韦林治疗慢性丙型肝炎患者临床疗效及安全性比较研究. 实用肝脏病杂志, 2018, 21(5): 729-732.
[2]Al Moussawi H, Polavarapu AD, Asti D, et al. Successful treatment of hepatitis c virus by ledipasvir/sofosbuvir in a cirrhotic patient with sickle cell disease and thalassemia minor. Case Rep Gastroenterol, 2018, 12(3): 629-632.
[3]Atsukawa M, Tsubota A, Kondo C, et al. Effectiveness and safety of community-based treatment with sofosbuvir plus ribavirin for elderly patients with genotype 2 chronic hepatitis C. Dig Liver Dis, 2017, 49(9): 1029-1035.
[4]Lotowska JM, Sobaniec-Lotowska ME, Sobaniec P, et al. Liver sinusoidal endothelial cells in morphogenesis of pediatric autoimmune hepatitis. Pol J Pathol, 2018, 69(4): 327-334.
[5]Baker MM, Hammad SF, Belal TS. Development and validation of a versatile HPLC-DAD method for simultaneous determination of the antiviral drugs daclatasvir, ledipasvir, sofosbuvir and ribavirin in presence of seven potential impurities. Drug Dev Ind Pharm, 2019, 45(7): 1111-1119.
[6]Chang YK, Tseng YT, Chen KH, et al. Long-term outcomes and risk factors of thyroid dysfunction during pegylated interferon and ribavirin treatment in patients with chronic hepatitis C infection in Taiwan. BMC Endocr Disord, 2019, 19(1): 36.
[7]杨松, 成军. 《丙型肝炎指南(2015年更新版)》解读之变革的HCV基因型. 中国肝脏病杂志(电子版), 2015, 7(4): 3-4.
[8]Poordad F, Sedghi S, Pockros PJ, et al. Efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir with low-dose ribavirin in patients with chronic hepatitis C virus genotype 1a infection without cirrhosis. J Viral Hepat, 2019, 26(8): 1027-1030.
[9]Piecha F, Gänßler JM, Jordan S, et al. Transjugular intrahepatic portosystemic shunt: a possible risk factor for direct-acting antiviral treatment failure in patients with hepatitis C? Hepatol Commun, 2019, 3(5): 614-619.
[10]Chen CH, Chen CH, Lin CL, et al. Real-world safety and efficacy of paritaprevir/ritonavir/ombitasvir plus dasabuvir±ribavirin in patients with hepatitis C virus genotype 1 and advanced hepatic fibrosis or compensated cirrhosis: a multicenter pooled analysis. Sci Rep, 2019, 9(1): 7086.
[11]张国范, 王芳芳, 郭春霞, 等. 递增剂量α-干扰素联合利巴韦林治疗代偿期丙型肝炎肝硬化患者安全性和有效性研究. 实用肝脏病杂志, 2016, 19(3): 345-346.
[12]Todorovska B, Caloska-Ivanova V, Dimitrova-Genadieva M, et al. Atorvastatin in combination with pegylated interferon and ribavirin provided high rate of sustained virological response in patients with genotype 3 hepatitis c virus. Open Access Maced J Med Sci, 2019, 7(10): 1641-1648.
[13]程丹颖, 刘晓民, 欧蔚妮, 等. 直接抗病毒药物治疗丙型肝炎肝硬化患者的疗效观察. 中华实验和临床感染病杂志(电子版), 2017, 11(6): 545-549.
[14]Samuel CE. Adenosine deaminase acting on RNA (ADAR1), a suppressor of double-stranded RNA-triggered innate immune responses. J Biol Chem, 2019, 294(5): 1710-1720.
[15]Kawaguchi T, Komori A, Fujisaki K, et al. Eltrombopag enables initiation and completion of pegylated interferon/ribavirin therapy in Japanese HCV-infected patients with chronic liver disease and thrombocytopenia. Exp Ther Med, 2019, 18(1): 596-604.
[16]Wu SH, Chu CJ, Huang YH, et al. Successful treatment with sofosbuvir and daclatasvir plus ribavirin in acute hepatitis C-infected patient with hepatic decompensation. J Chin Med Assoc, 2019, 82(7): 595-598.
[17]Preda CM, Baicus C, Sandra I, et al. Recurrence rate of hepatocellular carcinoma in patients with treated hepatocellular carcinoma and hepatitis C virus-associated cirrhosis after ombitasvir/paritaprevir/ritonavir+dasabuvir+ribavirin therapy. United Eur Gastroenterol J, 2019, 7(5): 699-708.
[18]Li X, Sjöstedt C, Sundquist J, et al. Familial association of attention-deficit hyperactivity disorder with autoimmune diseases in the population of Sweden. Psychiatr Genet, 2019, 29(2): 37-43.
[19]Cusato J, Allegra S, Boglione L, et al. VDR gene polymorphisms impact on anemia at 2 weeks of anti-HCV therapy: a possible mechanism for early RBV-induced anemia. Pharmacogenet Genomics, 2015, 25(4): 164-72.
[20]Soota K, Maliakkal B. Ribavirin induced hemolysis: a novel mechanism of action against chronic hepatitis C virus infection. World J Gastroenterol, 2014, 20(43): 16184-16190.
[21]Morsy KH, Zaghloul A, Mahmoud M. Can eicosapentaenoic acid maintain the original ribavirin dose or affect the response during the treatment course of chronic hepatitis C virus (HCV) patients? Turk J Gastroenterol, 2016, 27(1): 55-61.
[22]Ma YJ, Zhang HD, Wu CH, et al. Rapid CO breath test screening of drugs for protective effects on ribavirin-induced hemolysis in a rabbit model: a pilot study. J Breath Res, 2016, 10(3): 036010.
[23]Zwirtes R, Narasimhan P, Wind-Rotolo MM, et al. Mechanisms of hyperbilirubinemia during peginterferon lambda-1a therapy for chronic hepatitis c infection: A retrospective investigation. J Interferon Cytokine Res, 2016, 36(11): 644-651.

PR方案治疗慢性丙型肝炎患者ITPA基因rs1127354位点多态性与利巴韦林相关性溶血关系探讨^*

Impact of ITPA gene rs1127354 polymorphism on ribavirin-related hemolysis in patients with chronic hepatitis C receiving PR therapy

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	符垂师,张杰伟. α干扰素联合利巴韦林治疗儿童丙型肝炎患者病毒学应答率分析[J]. 实用肝脏病杂志, 2020, 23(3): 344-347.
[2]	张晓伟, 钟蕊. 索磷布韦和维帕他韦联合利巴韦林治疗基因2、3型慢性丙型肝炎患者近期疗效和耐受性观察^*[J]. 实用肝脏病杂志, 2020, 23(2): 191-194.
[3]	刘亿军, 段舒馨, 游春芳, 龚科. HFE基因多态性检测判断慢性丙型肝炎患者疾病活动的价值^*[J]. 实用肝脏病杂志, 2020, 23(2): 195-198.
[4]	张健珍, 曾春燕, 张春兰, 许敏, 李剑萍, 李慧慧, 关玉娟. 索非布韦联合达卡他韦治疗慢性丙型肝炎:真实世界临床研究[J]. 实用肝脏病杂志, 2020, 23(1): 30-33.
[5]	黄汉军, 鲁凤荣, 张灿. MRI联合血清维生素D预测慢性丙型肝炎患者肝纤维化临床价值探讨^*[J]. 实用肝脏病杂志, 2020, 23(1): 143-144.
[6]	潘美民, 李文娟, 蒋芳清, 杨丽晖, 谭永卫, 何娟, 阮建文, 蔡春琳. 慢性丙型肝炎患者血清IL-17A、FGF和IL-7水平与丙型肝炎病毒感染自发清除临床意义探讨^*[J]. 实用肝脏病杂志, 2019, 22(6): 840-843.
[7]	邓浩辉, 李晓强, 高洪波, 陈伟烈. HIV/HCV混合感染者与HCV感染者感染HCV基因型分析*[J]. 实用肝脏病杂志, 2019, 22(5): 656-659.
[8]	刘立, 李俊义, 杜映荣, 刘春云, 李卫昆, 王辉, 李惠敏, 常丽仙, 祁燕伟. 索磷布韦/达拉他韦治疗慢性丙型肝炎患者疗效及安全性分析：一项真实世界研究[J]. 实用肝脏病杂志, 2019, 22(3): 361-364.
[9]	蒋奕,刘冰. 慢性乙型肝炎与慢性丙型肝炎患者临床和肝组织病理学特征分析[J]. 实用肝脏病杂志, 2019, 22(2): 188-191.
[10]	吴静,东保吉,吴超. 慢性丙型肝炎患者外周血滤泡辅助性T淋巴细胞表面PD-1受体表达及意义研究^*[J]. 实用肝脏病杂志, 2019, 22(2): 192-195.
[11]	吴亚平,周冰清,蒋蓓莉. 慢性丙型肝炎患者发生重度肝纤维化相关因素分析^*[J]. 实用肝脏病杂志, 2019, 22(2): 196-199.
[12]	侯春阳, 马玉梅, 李方治. Peg-IFNα-2b联合利巴韦林治疗基因1/6型慢性丙型肝炎患者临床研究^*[J]. 实用肝脏病杂志, 2019, 22(1): 53-56.
[13]	周思思, 沈有秀, 李娟, 俞科贤. 慢性丙型肝炎和肝硬化患者外周血Th17和Treg细胞及其相关细胞因子水平变化^*[J]. 实用肝脏病杂志, 2018, 21(5): 689-692.
[14]	曹风华, 经继生, 赵伟, 江英骙, 马洁. 大剂量普通α-干扰素与聚乙二醇化α-干扰素联合利巴韦林治疗慢性丙型肝炎患者临床疗效及安全性比较研究^*[J]. 实用肝脏病杂志, 2018, 21(5): 729-732.
[15]	王婧婧, 张瑜, 董娜, 韩振坤, 翟景明. 慢性丙型肝炎外周血miR-1273g-3p水平变化及其诊断肝纤维化分期的效能分析*[J]. 实用肝脏病杂志, 2018, 21(3): 401-404.